• Shanghai Henlius Biotech revenue rose 27.3% to RMB 3.59 billion for the six months ended June 30, 2026.
• Total profit increased 10.33% to RMB 430.4 million, supported by higher core product volumes and overseas commercialization gains.
• R&D expenditure climbed to RMB 1.45 billion; expensed R&D rose to RMB 826 million as investment shifted toward innovative programs.
• Overseas product sales revenue reached RMB 105.3 million; overseas product profit was RMB 59.5 million, up more than four times.
• Non-IFRS profit rose to RMB 572.3 million; Non-IFRS EBITDA increased to RMB 904.1 million, reflecting stronger operating performance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294586), on August 21, 2026, and is solely responsible for the information contained therein.